- Home
- BSX vs GILD Comparison
BSX vs GILD Comparison
Compare BSX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSX
- GILD
- Stock Information
- Founded
- BSX 1979
- GILD 1987
- Country
- BSX United States
- GILD United States
- Employees
- BSX N/A
- GILD N/A
- Industry
- BSX Medical/Dental Instruments
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSX Health Care
- GILD Health Care
- Exchange
- BSX Nasdaq
- GILD Nasdaq
- Market Cap
- BSX 129.7B
- GILD 113.0B
- IPO Year
- BSX 1992
- GILD 1992
- Fundamental
- Price
- BSX $100.90
- GILD $92.96
- Analyst Decision
- BSX Strong Buy
- GILD Buy
- Analyst Count
- BSX 23
- GILD 26
- Target Price
- BSX $96.41
- GILD $98.17
- AVG Volume (30 Days)
- BSX 5.1M
- GILD 6.5M
- Earning Date
- BSX 02-05-2025
- GILD 02-11-2025
- Dividend Yield
- BSX N/A
- GILD 3.32%
- EPS Growth
- BSX 47.19
- GILD N/A
- EPS
- BSX 1.21
- GILD 0.10
- Revenue
- BSX $15,911,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- BSX $17.70
- GILD $6.50
- Revenue Next Year
- BSX $13.00
- GILD $0.36
- P/E Ratio
- BSX $83.47
- GILD $957.27
- Revenue Growth
- BSX 15.66
- GILD 3.31
- 52 Week Low
- BSX $59.85
- GILD $62.07
- 52 Week High
- BSX $101.07
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- BSX 79.18
- GILD 56.35
- Support Level
- BSX $93.20
- GILD $90.82
- Resistance Level
- BSX $97.13
- GILD $93.07
- Average True Range (ATR)
- BSX 1.56
- GILD 1.61
- MACD
- BSX 0.84
- GILD 0.08
- Stochastic Oscillator
- BSX 98.09
- GILD 80.85
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).